Showing results (41-50 of 65) with videos related to
Sort By:
Pageof 7
Molecular Cancer|May 4, 2025
The anti-diabetic PPARγ agonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancerEmine Atas, Kerstin Berchtold, Michaela Schlederer, et al.Hepatology (Baltimore, Md.)|July 5, 2011
Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in miceKristina M Mueller, Jan-Wilhelm Kornfeld, Katrin Friedbichler, et al.Scientific Reports|October 8, 2016
Hepatic Deletion of Janus Kinase 2 Counteracts Oxidative Stress in MiceMadeleine Themanns, Kristina M Mueller, Sonja M Kessler, et al.Cancer Cell|August 17, 2013
A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesisKaroline Kollmann, Gerwin Heller, Christine Schneckenleithner, et al.Nature Communications|January 22, 2014
A dual role for autophagy in a murine model of lung cancerShuan Rao, Luigi Tortola, Thomas Perlot, et al.Nature Communications|April 23, 2024
Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastomaPerla Pucci, Liam C Lee, Miaojun Han, et al.Oncotarget|June 17, 2015
AF1q is a novel TCF7 co-factor which activates CD44 and promotes breast cancer metastasisJino Park, Michaela Schlederer, Martin Schreiber, et al.Molecular Cancer|March 31, 2022
KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasisTanja Limberger, Michaela Schlederer, Karolina Trachtová, et al.Cell Death & Disease|October 14, 2016
Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformationTahereh Javaheri, Zahra Kazemi, Jan Pencik, et al.Cell Death & Disease|July 25, 2018
Correction: Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformationTahereh Javaheri, Zahra Kazemi, Jan Pencik, et al.Pageof 7